Cenerimod

Drug Profile

Cenerimod

Alternative Names: ACT-334441; lysosphingolipid receptor agonist - Actelion; S1P1 receptor modulator - Actelion; Second selective S1P1 receptor agonist - Actelion; Sphingosine 1 phosphate receptor modulators - Actelion; Sphingosine 1-phosphate receptor 1 agonists - Actelion

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Lysosphingolipid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus

Most Recent Events

  • 01 Feb 2017 Actelion completes a phase I/II trial in Systemic lupus erythematosus in Georgia, Russia, USA, Bulgaria, Ukraine, Belarus (PO) (NCT02472795)
  • 01 Dec 2016 Actelion completes a phase I trial in Systemic lupus erythematosus (In volunteers) in Netherlands (PO) (NCT02914223)
  • 14 Oct 2016 Phase-I clinical trials in Systemic lupus erythematosus (In volunteers) in Netherlands (PO) (NCT02914223)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top